The Cancer Testis Antigen PRAME As a Biomarker for Solid Tumor Cancer Management

Biomarkers in MedicineVol. 6, No. 5 General Content - EditorialThe cancer testis antigen PRAME as a biomarker for solid tumor cancer managementSteve Goodison & Virginia UrquidiSteve Goodison* Author for correspondenceCancer Research Institute, MD Anderson Cancer Center Orlando, 6900 Lake Nona Blvd, Orlando, FL 32827, USA. Search for more papers by this authorEmail the corresponding author at steven.goodison@orlandohealth.com & Virginia UrquidiCancer Research Institute, MD Anderson Cancer Center Orlando, 6900 Lake Nona Blvd, Orlando, FL 32827, USASearch for more papers by this authorPublished Online:17 Oct 2012https://doi.org/10.2217/bmm.12.65AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: breast cancercancer testis antigenleukemiaPRAMEReferences1 Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell122(6),835–847 (2005).Crossref, Medline, CAS, Google Scholar2 Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol. Cancer9,226 (2010).Crossref, Medline, Google Scholar3 Oehler VG, Guthrie KA, Cummings CL et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood114(15),3299–3308 (2009).Crossref, Medline, CAS, Google Scholar4 Santamaria C, Chillon MC, Garcia-Sanz R et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica93(12),1797–1805 (2008).Crossref, Medline, Google Scholar5 Dyrskjot L, Zieger K, Kissow Lildal T et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br. J. Cancer107(1),116–122 (2012).Crossref, Medline, CAS, Google Scholar6 Brenne K, Nymoen DA, Reich R, Davidson B. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am. J. Clin. Pathol.137(2),240–247 (2012).Crossref, Medline, CAS, Google Scholar7 Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin. Cancer Res.10(13),4307–4313 (2004).Crossref, Medline, CAS, Google Scholar8 Van ‘T Veer LJ, Dai H, Van De Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415(6871),530–536 (2002).Crossref, Medline, Google Scholar9 Van De Vijver MJ, He YD, Van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25),1999–2009 (2002).Crossref, Medline, CAS, Google Scholar10 Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100(14),8418–8423 (2003).Crossref, Medline, CAS, Google Scholar11 Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics23(1),30–37 (2007).Crossref, Medline, CAS, Google Scholar12 Sun Y, Urquidi V, Goodison S. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. Breast Cancer Res. Treat.119(3),593–599 (2010).Crossref, Medline, Google Scholar13 Sun Y, Todorovic S, Goodison S. Local-learning-based feature selection for high-dimensional data analysis. IEEE Trans. Pattern Anal. Mach. Intell.32(9),1610–1626 (2010).Crossref, Medline, Google Scholar14 Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br. J. Cancer99(3),398–403 (2008).Crossref, Medline, CAS, Google Scholar15 Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O’Driscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res. Treat.109(2),359–365 (2008).Crossref, Medline, CAS, Google Scholar16 Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer46(9),796–804 (2007).Crossref, Medline, CAS, Google Scholar17 Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk. Res.35(9),1219–1225 (2011).Crossref, Medline, CAS, Google Scholar18 Costessi A, Mahrour N, Tijchon E et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J.30(18),3786–3798 (2011).Crossref, Medline, CAS, Google Scholar19 De Carvalho DD, Binato R, Pereira WO et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene30(2),223–233 (2011).Crossref, Medline, CAS, Google Scholar20 Rezvani K, Yong AS, Tawab A et al.Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood113(10),2245–2255 (2009).Crossref, Medline, CAS, Google Scholar21 Griffioen M, Kessler JH, Borghi M et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin. Cancer Res.12(10),3130–3136 (2006).Crossref, Medline, CAS, Google Scholar22 Bollard CM, Gottschalk S, Leen AM et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood110(8),2838–2845 (2007).Crossref, Medline, CAS, Google Scholar23 Quintarelli C, Dotti G, Hasan ST et al. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood117(12),3353–3362 (2011).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByPRAME Promotes Cervical Cancer Proliferation and Migration via Wnt/β-Catenin Pathway Regulation16 March 2023 | Cancers, Vol. 15, No. 6PRAME Expression in Mucosal Melanoma of the Head and Neck Region13 March 2023 | American Journal of Surgical Pathology, Vol. Publish Ahead of PrintPRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics13 October 2022 | Histopathology, Vol. 50PRAME protein expression in DICER1 ‐related tumours16 March 2022 | The Journal of Pathology: Clinical Research, Vol. 8, No. 3Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions10 March 2022 | American Journal of Surgical Pathology, Vol. 46, No. 5DNA vaccines for cancer treatmentPreferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms11 May 2021 | The American Journal of Dermatopathology, Vol. 43, No. 11Comparison of adipophilin and recently introduced PReferentially expressed Antigen in MElanoma immunohistochemistry in the assessment of sebaceous neoplasms: A pilot study17 May 2021 | Journal of Cutaneous Pathology, Vol. 48, No. 10PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic LesionsSurgical Pathology Clinics, Vol. 14, No. 2Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2Prame complex27 January 2021 | Cell Death & Differentiation, Vol. 28, No. 6PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features10 September 2020 | Journal of Cutaneous Pathology, Vol. 47, No. 12Melanoma Biomarkers and Their Potential Application for In Vivo Diagnostic Imaging Modalities16 December 2020 | International Journal of Molecular Sciences, Vol. 21, No. 24T cell receptor therapy against melanoma—Immunotherapy for the future?30 September 2020 | Scandinavian Journal of Immunology, Vol. 92, No. 4Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors20 April 2020 | American Journal of Surgical Pathology, Vol. 44, No. 7Immunopeptidome screening to design An immunogenic construct against PRAME positive breast cancer; An in silico studyComputational Biology and Chemistry, Vol. 85Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma16 October 2019 | American Journal of Surgical Pathology, Vol. 44, No. 4The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancerCell Proliferation, Vol. 53, No. 3PRAME Expression in Melanocytic TumorsAmerican Journal of Surgical Pathology, Vol. 42, No. 11Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agentsMelanoma Research, Vol. 27, No. 1Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers7 September 2016 | Immunological Investigations, Vol. 45, No. 7PRAME expression and promoter hypomethylation in epithelial ovarian cancer13 June 2016 | Oncotarget, Vol. 7, No. 29A transcriptional target of androgen receptor, miR-421 regulates proliferation and metabolism of prostate cancer cellsThe International Journal of Biochemistry & Cell Biology, Vol. 73PRAME PROTEIN ARE LOCATED IN CELL NUCLEUS DURING ITS GENE IS HYPEREXPRESSED30 December 2015 | Russian Journal of Biotherapy, Vol. 14, No. 4Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes16 July 2015 | International Journal of Molecular Sciences, Vol. 16, No. 7DNA vaccine for cancer immunotherapy27 January 2015 | Human Vaccines & Immunotherapeutics, Vol. 10, No. 11Bioinformatics for spermatogenesis: annotation of male reproduction based on proteomics15 July 2013 | Asian Journal of Andrology, Vol. 15, No. 5 Vol. 6, No. 5 Follow us on social media for the latest updates Metrics Downloaded 316 times History Published online 17 October 2012 Published in print October 2012 Information© Future Medicine LtdKeywordsbreast cancercancer testis antigenleukemiaPRAMEFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download